Company Performance - Dentsply International reported quarterly earnings of $0.43 per share, exceeding the Zacks Consensus Estimate of $0.29 per share, and showing a slight increase from $0.42 per share a year ago, resulting in an earnings surprise of 48.28% [1] - The company posted revenues of $879 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.22%, although this represents a decline from year-ago revenues of $953 million [2] - Over the last four quarters, Dentsply has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Dentsply shares have declined approximately 27.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.45 on revenues of $911.58 million, and for the current fiscal year, it is $1.79 on revenues of $3.56 billion [7] - The estimate revisions trend for Dentsply is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which Dentsply belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Dentsply Sirona Reports First Quarter 2025 Results Charlotte, N.C., May 8, 2025 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2024. Foreign currency changes negatively impacted first quarter 2025 net sales by approximately ($30) million. Net income was $20 million, or $0.10 per share, compa ...

Financial Performance - Q1 2025 reported sales decreased by (7.7%) to $879 million compared to $953 million in Q1 2024 [17, 18] - Q1 2025 organic sales decreased by (4.4%) driven by an expected (4.0%) Byte impact [7] - Q1 2025 adjusted EBITDA margin expanded by 220 bps to 19.0% compared to 16.8% in Q1 2024 [7, 19] - Q1 2025 adjusted EPS increased by 3.7% to $0.43 compared to $0.42 in Q1 2024 [21, 22] - Q1 2025 operating cash flow decreased by (72%) to $7 million compared to $25 million in Q1 2024 [23, 24] Segment Performance - Essential Dental Solutions (EDS) reported a sales decrease of (2.7%), but organic sales increased by 0.4% to $353 million [26] - Orthodontic and Implant Solutions (OIS) reported a sales decrease of (20.0%), with organic sales down (17.7%) to $217 million, including a ~$40 million Byte impact [26] - Connected Technology Solutions (CTS) reported a sales decrease of (4.7%), with organic sales down (0.5%) to $235 million [26] - Wellspect Healthcare reported a sales increase of 3.4%, with organic sales up 8.0% to $74 million [26] Regional Performance - U S net sales decreased, with organic sales down (14.9%) due to a Byte impact of approximately ($40M) [28, 29] - Europe net sales decreased, with organic sales up 1.1% [28] - Rest of World net sales decreased, with organic sales up 3.1% [28] 2025 Outlook - The company maintains its FY25 outlook for organic sales at (4.0%) to (2.0%) [7, 30] - The company increases its FY25 outlook for reported sales to $3.60 billion - $3.70 billion due to F/X changes [7, 30] - The company maintains its FY25 outlook for adjusted EPS at $1.80 - $2.00 [7, 30]

Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today ann ...

Core Viewpoint - Dentsply International (XRAY) is expected to report a significant decline in quarterly earnings and revenues, with earnings per share projected at $0.29, a 31% decrease year-over-year, and revenues forecasted at $851.55 million, reflecting a 10.7% decline compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 1.5% over the past 30 days, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Key Metrics Projections - Analysts project 'Net sales- Connected Technology Solutions' to reach $233.14 million, a year-over-year decrease of 5.6% [5] - 'Net sales- Wellspect Healthcare' is expected to be $74.82 million, indicating a 5.4% increase from the same quarter last year [5] - 'Net sales- Essential Dental Solutions' is forecasted at $352.85 million, reflecting a 3.1% decline year-over-year [5] - 'Net sales- Orthodontic and Implant Solutions' is estimated to be $193.98 million, a significant decrease of 28.4% from the previous year [6] - 'Revenues- Rest of World' is projected at $190.83 million, down 13.7% year-over-year [6] - 'Revenues- Europe' is expected to be $356.44 million, indicating a 5.2% decline from the year-ago quarter [6] Stock Performance - Over the past month, Dentsply shares have returned +5.6%, underperforming the Zacks S&P 500 composite, which has seen a +10.6% change [7] - Currently, Dentsply carries a Zacks Rank 4 (Sell), suggesting potential underperformance in the near future [7]

Core Viewpoint - DENTSPLY SIRONA Inc. is set to release its first-quarter 2025 results on May 8, with expectations of revenue at $851.6 million and earnings at 29 cents per share, following a trend of earnings misses in previous quarters [1][8]. Group 1: Financial Performance and Estimates - The Zacks Consensus Estimate for revenues in Q1 2025 is $851.6 million, while the earnings consensus is 29 cents per share [1]. - The company has experienced an average earnings surprise of -9.34% over the past four quarters, indicating challenges in meeting market expectations [1]. Group 2: Impact of Byte Business Wind-Down - The ongoing wind-down of the Byte business is a significant factor, having caused a $62 million year-over-year decline in sales in Q4 2024 and a non-cash goodwill impairment of $370 million [2]. - The strategic shift away from the direct-to-consumer aligner segment towards clinician-directed models like SureSmile is expected to influence revenue dynamics as the company aims to fully exit Byte by mid-2025 [2]. Group 3: Regional Sales Performance - The U.S. region reported a 29.9% decline in year-over-year sales in Q4 2024, attributed to Byte's exit, CAD/CAM segment underperformance, and unfavorable distributor ordering patterns [3]. - Investors are anticipated to monitor signs of stabilization or rebound in U.S. demand, particularly in procedural categories such as implants and endodontics [3]. Group 4: Growth in Key Segments - Despite overall revenue pressure, SureSmile and imaging categories showed resilience, with SureSmile growing over 20% in Europe and imaging increasing nearly 13% globally in Q4 2024 [4]. - The company is expected to maintain momentum in these higher-margin, tech-enabled product lines in Q1 2025 [4]. Group 5: Product Launches and Innovations - DENTSPLY SIRONA launched PrimeScan 2, an upgraded intraoral scanner, aimed at enhancing clinical experience and workflow integration [5]. - The European launch of the MIS LYNX implant system received positive feedback, and the rollout of the DS Core digital cloud platform is expected to support procedural growth in restorative and implant dentistry [6].

Group 1 - Pro-Dex, Inc. (PDEX) shares increased by 5.1% to $66.92 in the last trading session, continuing an upward trend since March, with a total gain of 28.9% over the past four weeks [1] - The company is expected to report quarterly earnings of $0.47 per share, reflecting a year-over-year increase of 147.4%, with revenues projected at $17.7 million, up 23.9% from the previous year [2] - The consensus EPS estimate for Pro-Dex has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Group 2 - Pro-Dex operates within the Zacks Medical - Dental Supplies industry, where Dentsply International (XRAY) also belongs, with XRAY closing 3.2% higher at $13.71, but showing a -14.9% return over the past month [3] - Dentsply's consensus EPS estimate has decreased by 1% over the past month to $0.30, representing a decline of 28.6% compared to the previous year [4]

Core Viewpoint - Dentsply Sirona will host an investor conference call on May 8, 2025, to discuss its first quarter financial results [1][2]. Group 1: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies globally, with over a century of innovation [3]. - The company develops, manufactures, and markets a comprehensive range of dental and oral health products, as well as other consumable medical devices under a strong portfolio of world-class brands [3]. - Dentsply Sirona's innovative products aim to provide high-quality, effective, and connected solutions to enhance patient care and improve dental care safety [3]. Group 2: Investor Relations - The investor conference call will be available via a live webcast on the company's website [2]. - A replay of the conference call will also be accessible on the Investors section of the company's website after the event [2]. - For inquiries, investors can contact Andrea Daley, Vice President of Investor Relations, at +1-704-591-8631 or via email [4].

CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years o ...

Core Points - Dentsply Sirona will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025, at 3:00 pm ET [1] - A live audio webcast and replay will be available on the Dentsply Sirona website [2] Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies globally, with over a century of innovation [3] - The company develops, manufactures, and markets a comprehensive range of dental and oral health products, as well as consumable medical devices under a strong portfolio of brands [3] - Dentsply Sirona's innovative products aim to provide high-quality, effective, and connected solutions to enhance patient care and improve dental care safety [3] - The company is headquartered in Charlotte, North Carolina, and its shares are listed on Nasdaq under the symbol XRAY [3]